Credit Suisse Ag Compass Therapeutics, Inc. Transaction History

Credit Suisse Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.87 - $3.25 $7,584 - $13,182	-4,056 Reduced 5.24%	73,368 $144,000
Q2 2023 Aug 11, 2023	BUY	$2.64 - $3.48 $50,859 - $67,042	19,265 Added 33.12%	77,424 $246,000
Q1 2023 May 10, 2023	BUY	$3.14 - $5.48 $182,619 - $318,711	58,159 New	58,159 $190,000

91.9M

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $139M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.